8-K: Arcturus Therapeutics Reports Q3 2024 Results and Pipeline Progress, Achieves $25 Million Milestone

Arcturus Therapeutics announced its third quarter 2024 financial results, highlighted by a $25 million milestone achievement from the first sale of KOSTAIVE in Japan and progress in its clinical programs.

Summary

• Arcturus Therapeutics reported a net loss of $6.9 million for the third quarter of 2024, an improvement from the $16.2 million loss in the same period of 2023.
• Revenue for the quarter was $41.7 million, slightly down from $45.2 million in Q3 2023, primarily due to lower milestone payments from CSL, offset by revenue from a supply agreement for KOSTAIVE and increased BARDA revenue.
• The company achieved a $25 million commercial milestone with the first sale of KOSTAIVE in Japan.
• Operating expenses decreased to $52.4 million in Q3 2024 from $64.5 million in Q3 2023, mainly due to reduced research and development costs.
• Arcturus expects its cash runway to extend through the first quarter of fiscal year 2027, with $294.1 million in cash, cash equivalents, and restricted cash as of September 30, 2024.
• The company's cystic fibrosis and OTC deficiency Phase 2 studies are on track for proof-of-concept data in the first half of 2025.
• Arcturus anticipates a milestone payment related to potential European approval of KOSTAIVE in the first quarter of 2025.
• The company is planning to transfer its cystic fibrosis manufacturing process technology to ARCALIS.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant milestones achieved and progress in clinical programs. While there is a net loss, it is an improvement over the previous year, and the company has a solid cash runway. The positive clinical data and commercial success contribute to a favorable sentiment.

Positives

• Arcturus achieved a significant $25 million commercial milestone with the first sale of KOSTAIVE in Japan.
• KOSTAIVE showed superior 12-month durability compared to a conventional mRNA vaccine.
• Phase 3 results for KOSTAIVE XBB.1.5 were positive, meeting all primary and key secondary objectives.
• The company's Phase 2 studies for cystic fibrosis and OTC deficiency are progressing as planned.
• Arcturus anticipates a milestone payment related to potential European approval of KOSTAIVE.
• The company has a strong cash position with a runway extending through the first quarter of fiscal year 2027.
• Net loss improved significantly compared to the same quarter last year.

Negatives

• Revenue decreased slightly compared to the same quarter last year, primarily due to lower milestone payments from CSL.
• The company reported a net loss of $6.9 million for the quarter.
• Cash reserves decreased from $348.9 million at the end of 2023 to $294.1 million as of September 30, 2024.

Risks

• The company's future success depends on the continued advancement and commercialization of its pipeline programs.
• Clinical trial results may not be predictive of future clinical outcomes.
• The company's financial performance is subject to fluctuations in milestone payments and other revenue streams.
• There are risks associated with regulatory approvals and market acceptance of its products.
• The company's cash burn rate could impact its financial runway.

Future Outlook

Arcturus expects its cash runway to extend through the first quarter of fiscal year 2027 and anticipates continued progress in its clinical programs, including the release of interim Phase 2 proof-of-concept data in the first half of 2025. The company also expects a milestone payment related to potential European approval of KOSTAIVE in the first quarter of 2025.

Management Comments

• Joseph Payne, President & CEO, stated he is thrilled about the approval of KOSTAIVE for the COVID-19 JN.1 strain in Japan and the success of the STARR platform.
• Joseph Payne also mentioned that both ARCT-032 and ARCT-810 are on track for interim Phase 2 proof-of-concept clinical data in the first half of 2025.
• Andy Sassine, Chief Financial Officer, reported the first commercial milestone achieved from the CSL partnership for the first commercial sale of KOSTAIVE in Japan and anticipates another milestone related to potential European approval in the first quarter of 2025.

Industry Context

This announcement highlights Arcturus's progress in the mRNA therapeutics and vaccine space, particularly in infectious diseases and rare diseases. The company's partnership with CSL Seqirus and its joint venture in Japan, ARCALIS, are key to its strategy. The positive results from the KOSTAIVE studies and the advancement of its pipeline programs position Arcturus as a notable player in the mRNA field.

Comparison to Industry Standards

• The 12-month durability data for KOSTAIVE is a significant achievement, as many mRNA vaccines have shown waning immunity over time. This result compares favorably to other mRNA vaccines such as those from Moderna and Pfizer/BioNTech.
• The $25 million milestone payment for the first sale of KOSTAIVE in Japan is a positive indicator of commercial success, which is a key metric for biotech companies. This is comparable to other companies that have achieved similar milestones in their respective markets.
• The progress of the Phase 2 studies for ARCT-032 and ARCT-810 is in line with industry timelines for clinical development of novel therapeutics. The company's focus on rare diseases is also a growing trend in the biotech industry, as these areas often have unmet medical needs.

Stakeholder Impact

• Shareholders will be encouraged by the positive clinical data, the $25 million milestone achievement, and the improved financial performance.
• Employees will be motivated by the company's progress and the potential for future success.
• Patients with cystic fibrosis and OTC deficiency may benefit from the company's therapeutic programs.
• CSL Seqirus and Meiji Seika Pharma will benefit from the continued success of the partnership and the commercialization of KOSTAIVE.

Next Steps

• Arcturus will continue to enroll patients in the Phase 2 clinical program for ARCT-810.
• Arcturus will continue to enroll patients in the Phase 2 clinical program for ARCT-032.
• The company plans to transfer its cystic fibrosis manufacturing process technology to ARCALIS.
• The company anticipates a milestone payment related to potential European approval of KOSTAIVE in the first quarter of 2025.
• The company plans to file a U.S. BLA for KOSTAIVE in the first half of 2025.
• The company will share interim Phase 2 proof-of-concept data for ARCT-032 and ARCT-810 in the first half of 2025.

Key Dates

Keywords

Arcturus Therapeutics, KOSTAIVE, mRNA, Vaccine, Cystic Fibrosis, OTC Deficiency, Clinical Trials, Milestone, Financial Results, ARCT-032, ARCT-810, CSL Seqirus, ARCALIS